Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Lyell Immunopharma, Inc Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology June 26, 2024 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference June 03, 2024 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma to Participate in BofA Securities Health Care Conference May 07, 2024 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024 May 06, 2024 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting March 05, 2024 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023 February 28, 2024 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma Announces Participation in March Investor Conferences February 26, 2024 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma November 09, 2023 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023 November 07, 2023 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing October 31, 2023 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting September 27, 2023 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma to Participate in Upcoming Investor Conferences August 31, 2023 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023 August 08, 2023 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer July 05, 2023 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference June 07, 2023 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023 May 04, 2023 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma to Participate in BofA Securities Healthcare Conference May 02, 2023 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022 February 28, 2023 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference January 03, 2023 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer December 15, 2022 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma to Participate in BofA Securities Biotech Conference December 01, 2022 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series November 10, 2022 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results November 08, 2022 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors November 07, 2022 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma to Participate in Credit Suisse Healthcare Conference November 02, 2022 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors October 06, 2022 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting October 05, 2022 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer September 28, 2022 From Lyell Immunopharma, Inc Via GlobeNewswire Tickers LYEL Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.